In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN

Executive Summary

PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN, is projected for late 1994. The corticosteroid is designed for treatment of conjunctivitis associated with contact lens wear and allergies; results from Phase III clinical studies were presented by Phannos at an April 27 press conference in New York City. The Phase III results indicate that Lenoxin (lotepredol etabonate) has a lower incidence of side effects -- primarily elevated intraocular pressure -- compared to ophthalmic steroids now on the market, such as prednisolone and dexamethasone.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel